The British Society for Rheumatology developed guidelines for the management of idiopathic inflammatory myopathy among pediatric and adult patients.
The Company is currently evaluating DYN101 in the phase 1/2 UNITE-CNM trial in patients 16 years of age and older with CNM caused by mutations in the MTM1 or DNM2 gene.
Using the ACR/EULAR criteria, researchers studied the population-based incidence, prevalence, and mortality of dermatomyositis in adults.
Shashank Suresh, MD, takes us on a deep dive into the importance of immune-related adverse events, including immune-related myositis, which can be triggered by immune checkpoint inhibitor therapy.
The FDA has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.
Researchers evaluated clinical and histopathologic features in patients with dermatomyositis and circulating MDA5 autoantibodies, as defined by commercial-based testing.
The approval was based on data from the ProDERM study, which evaluated the efficacy and safety of Octagam 10% in 95 adults with dermatomyositis.
In this case-control autopsy series, study researchers evaluated skeletal muscle and myocardial inflammations in patients with severe COVID-19 who died.
In a study presented at the EULAR 2021 Virtual Congress, researchers evaluated the safety and efficacy of intravenous immunoglobulin therapy in adult patients with dermatomyositis.
This is the first report of hepatosplenic T-cell lymphoma in a patient with dermatomyositis treated with prednisolone and azathioprine.